PARIS & COPENHAGEN--(BUSINESS WIRE)--Regulatory News:
Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today published its consolidated financials for the period ending September 30, 2016 and provided an update on major milestones achieved during the third quarter of 2016.
